Literature DB >> 7923129

Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.

M E Dolan1, M Y Chae, A E Pegg, J H Mullen, H S Friedman, R C Moschel.   

Abstract

O6-Benzylguanine effectively inactivates the DNA repair protein, O6-alkylguanine-DNA alkyltransferase, leading to an increase in the therapeutic index of 1,3-bis(2-chloroethyl)-1-nitrosourea in nude mouse xenograft studies. To investigate the fate of this inactivator in mammalian systems, we examined its biodistribution and metabolism following i.p. administration of 8-[3H]-O6-benzylguanine to male Sprague-Dawley rats and BALB/c mice. Following administration to rats, there were significantly higher levels of radioactivity in liver than in lung, spleen, kidney, small intestine, and esophagus for up to 24 h. Major urinary metabolites were identified as O6-benzyl-7,8-dihydro-8-oxoguanine, N2-acetyl-O6-benzylguanine, and N2-acetyl-O6-benzyl-7,8-dihydro-8-oxoguanine. Debenzylated metabolites included guanine, 7,8-dihydro-8-oxoguanine, and N2-acetylguanine. In contrast to rat metabolism, acetylated derivatives were not found in mouse urine. However, O6-benzyl-7,8-dihydro-8-oxoguanine was a major metabolite in the mouse. O6-Benzyl-7,8-dihydro-8-oxoguanine was a very effective O6-alkylguanine-DNA alkyltransferase inactivator and exhibited a 50% effective dose in HT29 cell extracts of 0.3 microM compared to 0.2 microM for O6-benzylguanine. The O6-alkylguanine-DNA alkyltransferase depleting activity of N2-acetyl-O6-benzylguanine and N2-acetyl-O6-benzyl-7,8-dihydro-8-oxoguanine were, respectively, 120- and 325-fold lower than O6-benzylguanine in HT29 cell-free extracts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923129

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding.

Authors:  D S Daniels; C D Mol; A S Arvai; S Kanugula; A E Pegg; J A Tainer
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

2.  Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.

Authors:  Shanbao Cai; Haiyan Wang; Barbara Bailey; Aaron Ernstberger; Beth E Juliar; Anthony L Sinn; Rebecca J Chan; David R Jones; Lindsey D Mayo; Arthur R Baluyut; W Scott Goebel; Karen E Pollok
Journal:  Clin Cancer Res       Date:  2011-04-12       Impact factor: 12.531

3.  Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression.

Authors:  Yanlin Jiang; Shaoyu Zhou; George E Sandusky; Mark R Kelley; Melissa L Fishel
Journal:  Cancer Invest       Date:  2010-11       Impact factor: 2.176

4.  Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

Authors:  Jon Weingart; Stuart A Grossman; Kathryn A Carson; Joy D Fisher; Shannon M Delaney; Mark L Rosenblum; Alessandro Olivi; Kevin Judy; Stephen B Tatter; M Eileen Dolan
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

5.  In vivo roles of conjugation with glutathione and O6-alkylguanine DNA-alkyltransferase in the mutagenicity of the bis-electrophiles 1,2-dibromoethane and 1,2,3,4-diepoxybutane in mice.

Authors:  Sung-Hee Cho; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-11-06       Impact factor: 3.739

6.  Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.

Authors:  M E Dolan; A E Pegg; R C Moschel; B R Vishnuvajjala; K P Flora; M R Grever; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice.

Authors:  M C Bibby; M J Thompson; J A Rafferty; G P Margison; R S McElhinney
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

8.  Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.

Authors:  B Geoerger; G Vassal; F Doz; J O'Quigley; M Wartelle; A J Watson; M-A Raquin; D Frappaz; P Chastagner; J-C Gentet; H Rubie; D Couanet; A Geoffray; L Djafari; G P Margison; F Pein
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

9.  Development of a Radiotracer for PET Imaging of the SNAP Tag.

Authors:  Xinling Li; Xiaochun Yang; Zhijian Li; Xiaobin Zheng; Yong-Jian Peng; Wenjie Lin; Ling Zhou; Dehai Cao; Minyi Situ; Qingqiang Tu; Huiqiang Huang; Wei Fan; Guokai Feng; Xiaofei Zhang
Journal:  ACS Omega       Date:  2022-02-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.